TScan Therapeutics, Inc. Share Price
TCRXTScan Therapeutics, Inc. Stock Performance
Open $1.10 | Prev. Close $1.12 | Circuit Range N/A |
Day Range $1.07 - $1.12 | Year Range $0.88 - $2.56 | Volume 14,966 |
Average Traded $1.10 |
TScan Therapeutics, Inc. Share Price Chart
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
26-Feb-26 | $1.10 | $1.11 | +0.00% |
26-Feb-26 | $1.10 | $1.11 | +6.19% |
24-Feb-26 | $1.07 | $1.05 | +3.55% |
23-Feb-26 | $1.00 | $1.01 | +0.40% |
20-Feb-26 | $1.04 | $1.01 | -1.94% |
19-Feb-26 | $1.03 | $1.03 | -0.48% |
18-Feb-26 | $1.01 | $1.03 | +7.81% |